Vertex Pharmaceuticals Earning Before Interest and Taxes EBIT Trend

VRTX -- USA Stock  

Earning Report: October 30, 2019  

This module enables investors to look at Vertex Pharmaceuticals various fundamental indicators over time in order to gain insight into the company future performance. Macroaxis historical fundamental analysis tools allow evaluation of not only typical financial statement drivers such as Direct Expenses of 291.1 M, Cost of Revenue of 125.5 M or Gross Profit of 1.2 B, but also many exotic indicators such as Interest Coverage of 11.8293, Long Term Debt to Equity of 0.354 or PPandE Turnover of 4.1348. This module is a perfect complement to use when analyzing Vertex Pharmaceuticals Valuation or Volatility. It can also complement various Vertex Pharmaceuticals Technical models. Also please take a look at analysis of Vertex Pharmaceuticals Correlation with competitors.

Vertex Pharmaceuticals Earning Before Interest and Taxes EBIT Marginal Breakdown

Showing smoothed Earning Before Interest and Taxes EBIT of Vertex Pharmaceuticals Incorpor with missing and latest data points interpolated. Earnings Before Interest and Tax is calculated by adding [TaxExp] and [IntExp] back to [NetInc].
Earning Before Interest and Taxes EBIT10 Years Trend
Increasing
Stable
 Earning Before Interest and Taxes EBIT 
      Timeline 

Vertex Pharmaceuticals Regression Statistics

Arithmetic Mean(273,750,434)
Coefficient Of Variation(110.89)
Mean Deviation 273,431,638
Median(92,267,000)
Standard Deviation 303,550,809
Range 821,872,000
R Value 0.31
R Squared 0.1
Significance 0.33
Slope 26,041,130

Vertex Pharmaceuticals Earning Before Interest and Taxes EBIT Over Time

2016 (13,955,000) 
2018 (16,048,250) 
2019 (179,043,964) 

Other Fundumenentals of Vertex Pharmaceuticals

Search macroaxis.com